The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian adenocarcinomas, according to a news release on April 29 from Shorla Oncology, the ...

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical ...

Despite the COVID-19 pandemic and related health care disruptions that caused a decrease in cancer incidence, overall cancer ...